Twist Bioscience (NASDAQ:TWST) CFO Sells $120,000.00 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 3,000 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $40.00, for a total value of $120,000.00. Following the completion of the transaction, the chief financial officer directly owned 137,031 shares of the company’s stock, valued at approximately $5,481,240. This trade represents a 2.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Adam Laponis also recently made the following trade(s):

• On Friday, January 9th, Adam Laponis sold 2,738 shares of Twist Bioscience stock. The shares were sold at an average price of $35.26, for a total value of $96,541.88.
• On Thursday, October 30th, Adam Laponis sold 5,517 shares of Twist Bioscience stock. The shares were sold at an average price of $31.44, for a total transaction of $173,454.48.

Twist Bioscience Stock Up 0.3%

TWST stock opened at $41.41 on Friday. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $55.33. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.33 and a current ratio of 3.64. The firm’s fifty day moving average is $32.42 and its 200 day moving average is $31.26. The firm has a market cap of $2.54 billion, a PE ratio of -31.61 and a beta of 2.19.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Friday, November 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Twist Bioscience had a negative return on equity of 27.40% and a negative net margin of 20.63%.The firm had revenue of $99.01 million for the quarter, compared to analysts’ expectations of $97.40 million. On average, research analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. EdgePoint Investment Group Inc. grew its holdings in Twist Bioscience by 71.1% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock valued at $114,876,000 after buying an additional 1,696,377 shares in the last quarter. Artisan Partners Limited Partnership boosted its position in shares of Twist Bioscience by 26.7% during the 3rd quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock valued at $180,403,000 after acquiring an additional 1,349,867 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Twist Bioscience by 151.5% in the third quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock valued at $50,479,000 after purchasing an additional 1,080,722 shares during the period. Balyasny Asset Management L.P. increased its position in Twist Bioscience by 934.0% during the second quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company’s stock worth $23,113,000 after purchasing an additional 567,481 shares during the last quarter. Finally, Baillie Gifford & Co. increased its position in Twist Bioscience by 62.8% during the third quarter. Baillie Gifford & Co. now owns 1,262,739 shares of the company’s stock worth $35,533,000 after purchasing an additional 487,052 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts have weighed in on TWST shares. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Stephens assumed coverage on shares of Twist Bioscience in a research report on Monday, November 3rd. They set an “overweight” rating and a $41.00 price target for the company. Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. TD Cowen boosted their price objective on Twist Bioscience from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Finally, Evercore ISI reissued an “outperform” rating and set a $42.00 target price on shares of Twist Bioscience in a report on Monday, January 5th. Nine analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $44.67.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.